#vasomotor symptoms | Explore Tumblr posts and blogs

stevenwilliam12 · 6 days ago

Text

Epidemiology and Insights into the Overt Hepatic Encephalopathy Market Outlook

Overt Hepatic Encephalopathy (OHE) is a severe neurological complication of advanced liver disease, particularly cirrhosis. Characterized by confusion, altered consciousness, and even coma in extreme cases, OHE arises from the accumulation of toxins like ammonia in the bloodstream due to impaired liver function. As the global prevalence of chronic liver diseases increases, the Overt Hepatic Encephalopathy market is gaining significant attention from healthcare providers and pharmaceutical companies.

Market Insight

The Overt Hepatic Encephalopathy market size is expected to grow substantially through 2032, driven by the rising prevalence of cirrhosis, aging populations, and the increased focus on liver disease management. Current treatments, such as lactulose and rifaximin, aim to reduce toxin levels and manage symptoms. However, the high recurrence rate of OHE underscores the need for novel therapies that address the underlying pathophysiology.

In recent years, pharmaceutical companies have intensified their efforts to develop advanced treatments for OHE. Innovations in precision medicine and the emergence of combination therapies are likely to reshape the market landscape. Additionally, growing awareness about the condition and improved diagnostic techniques are driving earlier interventions, which further contribute to market growth.

Epidemiology Forecast

The Overt Hepatic Encephalopathy Epidemiology Forecast indicates a steady rise in cases globally due to the increasing prevalence of liver diseases such as hepatitis and non-alcoholic fatty liver disease (NAFLD). According to estimates, 30-40% of cirrhotic patients experience at least one episode of OHE, with recurrence rates as high as 50% within a year.

Regions with high rates of viral hepatitis, alcohol-related liver disease, and metabolic syndrome, such as Asia-Pacific and North America, are anticipated to report the largest patient populations. Enhanced screening programs and access to healthcare in these regions will likely improve diagnosis rates, further influencing epidemiological trends.

Market Forecast

Through 2032, the Overt Hepatic Encephalopathy market size is poised for significant growth, supported by ongoing clinical trials, increased research funding, and advances in therapeutics. The market is also expected to benefit from the development of targeted therapies that address ammonia metabolism and reduce systemic inflammation.

Conclusion

The OHE market represents a critical area of growth and innovation within liver disease management. With rising patient numbers and advancements in treatment options, the Overt Hepatic Encephalopathy market offers significant opportunities for improving patient outcomes and addressing a major public health challenge.

Latest Reports

0 notes

drchristophedelongsblog · 12 days ago

Text

Algoneurodystrophy : hard luck !

Algoneurodystrophy, also known as complex regional pain syndrome (CRPS), is a chronic and complex condition characterised by intense and persistent pain in a part of the body, often following minor trauma or surgery.

What are the symptoms?

The symptoms of algoneurodystrophy can vary from person to person, but generally include :

- Severe pain: The pain is often disproportionate to the initial injury and may spread to a wider area.

- Skin changes: The skin may become red, shiny and warm, or pale, cold and oozing.

- Swelling: Tissues may become swollen and stiff.

- Bone changes: Changes in bone density may occur.

- Vasomotor disorders: Changes in skin temperature and colour may be observed.

- Sensory disorders: Burning, tingling or pins and needles may be present.

What causes it?

The exact causes of algoneurodystrophy are not yet fully understood, but it is thought to result from a disruption of the central and peripheral nervous system after a triggering event, such as:

- Trauma (fracture, sprain, dislocation)

- surgery

- A cerebrovascular accident

- myocardial infarction

How is it diagnosed?

Algoneurodystrophy is often difficult to diagnose because there is no specific test. The doctor bases his diagnosis on the patient's symptoms and the results of complementary examinations, such as :

- X-rays: to assess bone changes.

- Bone scan: To detect an increase in metabolic activity in the affected area.

- MRI: To visualise soft tissue and nerves.

What treatments are available?

The treatment of algoneurodystrophy is complex and must be tailored to each patient. It may include :

- Medication: Analgesics, anti-inflammatories, drugs to regulate neuropathic pain.

- Physiotherapy: Gentle, progressive exercises to maintain mobility and reduce pain.

- Physical therapies: Heat, cold, ultrasound.

- Injectable medicines: Corticosteroids or local anaesthetics.

- Transcutaneous electrical nerve stimulation (TENS).

- Behavioural and cognitive therapies: To help manage pain and anxiety.

In short, algoneurodystrophy is a complex and often disabling disease that requires multidisciplinary care. If you think you suffer from this disease, it is important to consult a specialist doctor.

Go further

#algoneurodystrophy #CRPS (for Complex Regional Pain Syndrome)#chronic pain #pain #inflammation #health #wellbeing #complexpain syndrome #neuropathic pain #physiotherapy #rehabilitation #medicine #treatment #chronicle

0 notes

womencorner · 14 days ago

Text

7 Menopause Tips from the Experts: Navigating the Change Like a Pro

Hot flashes and night sweats. Sound familiar? They’re not just fleeting annoyances; they’re the notorious symptoms of menopause, and they can sometimes feel like they’re taking over your life. But don’t worry — you’re not alone, and you don’t have to just grin and bear it.

Have you ever been standing in line at the grocery store, minding your own business, and then suddenly, you’re drenched in sweat, feeling as if the world’s temperature has skyrocketed, and you’re about to strip down — but everyone around you is calmly going about their day? Yeah, that’s menopause. It's that relentless heat wave that seems to strike at the worst possible moments.

If you’re in that golden window between 45 and 55, you can probably attribute these experiences to menopause. The transition, as you’ve no doubt noticed, is wildly different for each woman. However, vasomotor symptoms (VMS) — the technical term for those hot flashes and night sweats — are almost universal. And the kicker? These symptoms can persist for years.

Learn more: https://www.womenncorner.com/2024/11/7-menopause-tips-from-experts.html

#menopause #women health #exercise #women #big breasted women #beautiful women #old women #old woman

0 notes

vfxbloger · 20 days ago

Text

0 notes

ipharmacyeg-blog · 20 days ago

Text

Rinoclenil Nasal Spray: Benefits, Usage, and Safety Tips

Struggling with nasal allergies? Discover Rinoclenil Nasal Spray for targeted relief! Learn how this glucocorticoid spray reduces inflammation and eases symptoms. Check out our complete guide for usage, benefits, and safety tips. 🌼 #AllergyRelief #NasalH

Rinoclenil Nasal Spray is a highly effective medication designed to manage and relieve symptoms of various forms of rhinitis, including seasonal allergies and vasomotor rhinitis. This blog post will provide a comprehensive guide on Rinoclenil, covering its purpose, how to use it, potential side effects, and critical safety precautions. Table of Contents What is Rinoclenil Nasal Spray? How Does…

#NASAL PREPARATIONS

0 notes

vitaldirect · 2 months ago

Text

#menopause specialist nyc #menopause treatment tampa

0 notes

deshpandeisha · 2 months ago

Text

Innovative Approaches to Menopausal Therapy: Balancing Hormones Naturally

The global menopausal therapy market size was USD 16.10 Billion in 2022 and is expected to register a steady revenue CAGR of 5.3% during the forecast period, according to latest analysis by Emergen Research. Increasing prevalence of post-menopausal symptoms owing to shift towards a sedentary lifestyle and rising vasomotor and menopausal symptoms, such as night sweats and hot flashes, among women during menopausal transition are major factors driving market revenue growth. Menopause is a natural stage of aging, in which a woman's period and her ovaries cease to act reproductively. This usually happens between the age of 45 and 55. Average age in the UK is 51, however, one in every 100 women experiences menopause before the age of 40.

The analysis of the recent advancements in the Menopausal Therapy industry and trends driving the growth of the market. It is an investigative study covering analysis of market drivers, restraints, challenges, threats, and growth prospects in the global Menopausal Therapy market. The global Menopausal Therapy market report is a methodical research of the Menopausal Therapy market done by extensive primary and secondary research. The fundamental purpose of the Menopausal Therapy market report is to offer an accurate and strategic analysis of the Menopausal Therapy business sphere.

Get Download Pdf Sample Copy of this Report@ https://www.emergenresearch.com/request-sample/1676

Competitive Terrain:

The global Menopausal Therapy industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.

The leading market contenders listed in the report are:

Bayer AG, Theramex, AbbVie Inc., Abbott Laboratories, Pure Encapsulations, LLC, Rainbow Lights, Pfizer Inc., Eli Lily and Company, Cipla Inc., and Amgen Inc.

Key market aspects studied in the report:

Market Scope: The report explains the scope of various commercial possibilities in the global Menopausal Therapy market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.

Competitive Outlook: The leading companies operating in the Menopausal Therapy market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.

Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Menopausal Therapy market.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now)@ https://www.emergenresearch.com/request-discount/1676

Market Segmentations of the Menopausal Therapy Market

This market is segmented based on Types, Applications, and Regions. The growth of each segment provides accurate forecasts related to production and sales by Types and Applications, in terms of volume and value for the period between 2022 and 2030. This analysis can help readers looking to expand their business by targeting emerging and niche markets. Market share data is given on both global and regional levels. Regions covered in the report are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Research analysts assess the market positions of the leading competitors and provide competitive analysis for each company. For this study, this report segments the global Menopausal Therapy market on the basis of product, application, and region:

Segments Covered in this report are:

Product Outlook (Revenue, USD Billion; 2019-2032)

Hormone Therapy

Non-hormone Therapy

Distribution Channel Outlook (Revenue, USD Billion; 2019-2032)

Hospital Pharmacies

Retail Pharmacies

Online

Regional Outlook (Revenue, USD Billion; 2019–2032)

North America

U.S.

Canada

Mexico

Europe

Germany

France

Italy

Spain

Benelux

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Rest of APAC

Latin America

Brazil

Rest of LATAM

Middle East & Africa

Saudi Arabia

UAE

South Africa

Turkey

Rest of Middle East & Africa

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/menopausal-therapy-market

Major Geographies Analyzed in the Report:

North America (U.S., Canada)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

ToC of the report:

Chapter 1: Market overview and scope

Chapter 2: Market outlook

Chapter 3: Impact analysis of COVID-19 pandemic

Chapter 4: Competitive Landscape

Chapter 5: Drivers, Constraints, Opportunities, Limitations

Chapter 6: Key manufacturers of the industry

Chapter 7: Regional analysis

Chapter 8: Market segmentation based on type applications

Chapter 9: Current and Future Trends

Request Customization as per your specific requirement@ https://www.emergenresearch.com/request-for-customization/1676

About Us:

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: [email protected]

Visit for More Insights: https://www.emergenresearch.com/insights

Explore Our Custom Intelligence services | Growth Consulting Services

Trending Titles: Geocell Market | Pancreatic Cancer Treatment Market

Latest Report: Ceramic Tiles Market | Life Science Analytics Market

0 notes

mcatmemoranda · 1 year ago

Text

From UpToDate:

Epidemiology – Vasomotor symptoms (VMS) or "hot flashes" are the most common complaint during the menopausal transition, occurring in up to 80 percent of women during the late transition (figure 1). However, only approximately 20 to 30 percent of women seek medical attention for treatment.

●Typical symptoms – Hot flashes typically begin as the sudden sensation of heat centered on the upper chest and face that rapidly becomes generalized. The sensation of heat lasts from two to four minutes and is often associated with profuse perspiration and occasionally palpitations (see 'Typical symptoms' above). VMS at night can cause significant sleep disturbances in many women.

Four different trajectories of menopausal symptoms occur with nearly equal frequency: early onset 18.4 percent, onset near final menstrual period with later decline 29.0 percent, early onset with persistently high frequency 25.6 percent, and persistently low frequency 27.0 percent (figure 2).

●Management

•Mild symptoms – Individuals with mild hot flashes usually do not seek or require pharmacologic intervention. Simple lifestyle changes such as keeping the core body temperature cool are often adequate to manage symptoms.

•Moderate to severe symptoms

-Hormone therapy – For postmenopausal women with moderate to severe VMS (and no history of breast cancer or cardiovascular disease nor moderate to high risk of these diseases), we use low-dose estrogen plus progestin therapy (or estrogen alone if no uterus). Additional information on menopausal hormonal therapy (MHT), including its risks and benefits, potential candidates for therapy, as well as information on dose, regimens, and duration of therapy are discussed in detail separately.

-Nonhormonal options – For women with moderate to severe hot flashes occurring both in the daytime and at night, in whom estrogen is contraindicated, not well tolerated, or for women who have stopped estrogen and are experiencing recurrent symptoms but wish to avoid resuming estrogen, we suggest nonhormonal therapies such as selective serotonin reuptake inhibitors (SSRIs), or gabapentin (Grade 2C).

#menopause #hot flashes #vasomotor symptoms

1 note · View note

stomeranclels451 · 2 years ago

Text

https://community.wongcw.com/blogs/297886/Vasomotor-Symptoms-Market-2022-Trends-Research-Analysis-Review-Forecast-2030

Vasomotor Symptoms Market Analysis, Cost, Production Value, Price, Gross Margin and Competition Forecast to 2027

#Vasomotor Symptoms

0 notes

generalmarketresearch-blog · 1 year ago

Text

#Vasomotor Symptoms Treatment Market

0 notes

stevenwilliam12 · 6 days ago

Text

Game-Changers in NASH: Novel Therapeutics Shaping the Future of Care

Non-Alcoholic Steatohepatitis (NASH), a severe form of non-alcoholic fatty liver disease (NAFLD), continues to pose significant challenges due to its complex pathophysiology and lack of approved therapies. Characterized by liver inflammation, fibrosis, and fat accumulation, NASH can progress to cirrhosis or hepatocellular carcinoma. The NASH treatment market is witnessing groundbreaking developments with the emergence of novel drug classes that address the multifaceted nature of the disease.

Transforming the NASH Pipeline: Targeted Therapies

The NASH pipeline features a range of innovative drugs under development, targeting diverse pathways involved in the disease's progression. This includes agents designed to reduce liver fat, combat inflammation, and slow fibrosis. Novel drug classes making waves in the NASH treatment market include:

1. Thyroid Hormone Receptor Beta Agonists (THR-B)

THR-B agonists, like resmetirom, focus on reducing liver fat content by enhancing lipid metabolism. Their targeted action minimizes systemic side effects, making them a promising option in the NASH pipeline.

2. FXR Agonists

Farnesoid X receptor (FXR) agonists, such as obeticholic acid, aim to reduce fibrosis by regulating bile acid synthesis and anti-inflammatory pathways. While effective in improving liver histology, these drugs for the treatment of NASH are being optimized to balance efficacy with tolerability.

3. PPAR Agonists

Peroxisome proliferator-activated receptor (PPAR) agonists, including lanifibranor, are gaining traction for their ability to address multiple aspects of NASH, including steatosis, inflammation, and fibrosis. Their multi-targeted approach positions them as a cornerstone in the evolving NASH treatment market.

4. Anti-Fibrotic Agents

Drugs like simtuzumab directly target fibrosis pathways, offering potential solutions to one of the most critical and irreversible aspects of NASH progression.

Market Dynamics and Future Outlook

The NASH treatment market is projected to expand significantly, driven by the growing prevalence of obesity and metabolic syndrome, key risk factors for the disease. Ongoing clinical trials in the NASH pipeline hold promise for addressing the unmet needs of patients worldwide.With innovations in drug development and a deeper understanding of disease biology, the future of drugs for the treatment of NASH looks increasingly promising. As these novel therapies reach the market, they are set to revolutionize care, offering hope to millions of NASH patients globally.

Latest Reports

0 notes

menoplus0 · 3 months ago

Text

Natural Supplements for Managing Menopause: A Comprehensive Guide

Black Cohosh

Black cohosh is one of the most well-known herbal remedies for menopausal symptoms. It has been used for centuries by Native Americans to treat a variety of female reproductive issues, including menstrual cramps and hot flashes. Research shows that black cohosh may help reduce the severity and frequency of hot flashes, night sweats, and other vasomotor symptoms associated with menopause. Additionally, it may have a mild effect on mood, helping to alleviate anxiety and depression in some women.

Red Clover

Red clover is a plant that contains isoflavones, compounds that mimic estrogen in the body. These plant-based estrogens may help regulate hormone levels and reduce menopausal symptoms like hot flashes, bone density loss, and cardiovascular issues. Red clover is often recommended for women who want to avoid hormone replacement therapy but still seek relief from estrogen-related symptoms.

Maca Root

Maca root, a plant native to the high Andes of Peru, Menopause Natural Supplements has gained popularity as a natural remedy for balancing hormones during menopause. Rich in essential nutrients like vitamins, minerals, and amino acids, maca root is believed to support the endocrine system, helping to regulate hormone production. Women who take maca root may experience reduced hot flashes, improved energy levels, and enhanced libido. Additionally, maca may improve mood and reduce feelings of anxiety and depression, which are often prevalent during menopause.

Flaxseed

Flaxseed is a rich source of lignans, which are plant compounds that have weak estrogenic properties. These lignans may help balance hormone levels and provide relief from hot flashes and night sweats. Flaxseed is also high in omega-3 fatty acids, which can support heart health—a major concern for postmenopausal women. Adding ground flaxseed to your diet or taking flaxseed oil supplements can help support overall well-being during menopause.

Vitamin D and Calcium

As women go through menopause, Dry Vaginal Cream the decline in estrogen can lead to decreased bone density and a higher risk of osteoporosis. To maintain strong bones, it's important to ensure adequate intake of vitamin D and calcium. Vitamin D helps the body absorb calcium, while calcium itself is essential for maintaining bone strength. These supplements, when taken together, can help prevent bone loss and reduce the risk of fractures as you age.

Evening Primrose Oil

Evening primrose oil is another popular supplement for menopausal women. It contains gamma-linolenic acid (GLA), an omega-6 fatty acid that may help reduce inflammation and promote hormonal balance. Women who take evening primrose oil may experience relief from breast tenderness, mood swings, and hot flashes.

0 notes

delveinsight12 · 4 months ago

Text

Hot Flashes Market expected to rise | Companies- Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, Pherin Pharmaceuticals, expected to drive market

The Hot Flashes market growth is driven by factors like increase in the prevalence of Hot Flashes, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Hot Flashes market report also offers comprehensive insights into the Hot Flashes market size, share, Hot Flashes epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Hot Flashes market size growth forward.

Some of the key highlights from the Hot Flashes Market Insights Report:

Several key pharmaceutical companies, including Veru Healthcare, Fervent Pharmaceuticals, Ogeda, Bayer, Lundbeck A/S, TherapeuticsMD, MenoGeniX, Mitsubishi Tanabe Pharma, QUE Oncology, Pherin Pharmaceuticals, and others, are developing novel products to improve the Hot Flashes treatment outlook.

The total Hot Flashes market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.

As per DelveInsight analysis, the Hot Flashes market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Hot Flashes Market Landscape

Hot Flashes Overview

Hot flashes (HFs) are a rapid and exaggerated heat dissipation response, consisting of profuse sweating, peripheral vasodilation, and feelings of intense, internal heat. They are triggered by small elevations in core body temperature (Tc) acting within a greatly reduced thermoneutral zone, i.e., the Tc region between the upper (sweating) and lower (shivering) thresholds.

Hot flashes (HFs) are the most common symptom of the climacteric and are reported as feelings of intense warmth along with sweating, flushing, and chills. More than 80% of women experience hot flashes (HFs) during menopause. Defined by transient sensations of heat, sweating, flushing, anxiety, and chills lasting for 1–5 min, HFs can cause considerable distress especially when severe and frequent.

Among various factors reported to be associated with increase in incidence of HFs, a consistent association has been found only with obesity, African descent, lower socioeconomic status, presence of premenstrual syndrome, sedentary lifestyle, and smoking. HFs are characterized by excessive vasodilation of peripheral vasculature to lose heat in the setting of abnormal hypothalamic thermoneutral zone. While normal women initiate mechanisms of heat loss, once core body temperature increases by 0.4°C, women with HFs initiate vasodilatory response with a much smaller increase in core body temperature. It is peripheral vasodilatory response that results in profuse sweating and sensation of intense heat.

Do you know the treatment paradigms for different countries? Download our Hot Flashes Market Sample Report

Recent Highlights from the Hot Flashes Market Report:

In April, Fervent Pharmaceuticals has initiated a virtual at home Phase II clinical trial of its new product to treat the symptoms of moderate to severe hot flashes, night sweats and night-time awakenings due to hot flashes in women. Named M2S Hot Flash Study, the trial will analyse the peri- and post-menopausal therapy to treat hot flashes and night sweats.

In January 2020, Veru Inc, developing novel medicines for the management of prostate cancer, today announced positive top line data interim results from its Phase 2 clinical study of Zuclomiphene citrate, a nonsteroidal oral estrogen receptor agonist, for the treatment of androgen deprivation hormone therapy (ADT) induced hot flashes, also known as vasomotor symptoms, in men who have advanced prostate cancer. Zuclomiphene appears to be well tolerated as there have been no reports of drug related serious adverse events nor drug related severe adverse events and no observations of adverse events of special interest, such as breast enlargement or pain, or venothromboembolic events (blood clots in legs or lungs, or stroke) in the safety database for the Phase 2 clinical study.

Hot Flashes Epidemiology Segmentation

DelveInsight’s Hot Flashes market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Hot Flashes historical patient pools and forecasted Hot Flashes patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Hot Flashes Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

Hot Flashes Prevalence

Age-Specific Hot Flashes Prevalence

Gender-Specific Hot Flashes Prevalence

Diagnosed and Treatable Cases of Hot Flashes

Visit for more @ Hot Flashes Epidemiological Insights

Hot Flashes Treatment Market

The Hot Flashes market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Hot Flashes market trends by analyzing the impact of current Hot Flashes therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Hot Flashes market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Hot Flashes market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Hot Flashes market in 7MM is expected to witness a major change in the study period 2019-2032.

Hot Flashes Emerging Drugs

Fezolinetant: Astellas Pharma

Fezolinetant is an investigational selective neurokinin-3 (NK3) receptor antagonist. The safety and efficacy of fezolinetant are under investigation and have not been established. If approved by regulatory authorities, fezolinetant would be a first-in-class, nonhormonal treatment option to reduce the frequency and severity of VMS associated with menopause.

Elinzanetant: Bayer

Elinzanetant is a first-in-class, non-hormonal, orally administered, dual neurokinin-1,3 receptor antagonist currently in clinical development for the treatment of vasomotor symptoms during menopause. Elinzanetant addresses vasomotor symptoms by modulating a group of oestrogen sensitive neurons in the hypothalamus in the brain (the KNDy neurons), that due to the absence of oestrogen, become hyperactive in menopausal women and consequently disrupt body heat control mechanisms resulting in the debilitating vasomotor symptoms of hot flashes.

Fezolinetant: Ogeda

Fezolinetant (ESN364) is a proprietary, oral, small-molecule, discovered and developed by Ogeda for the purpose of the treatment of women’s health disorders. Fezolinetant’s mechanism of action to mimic the neuronal effects of estrogen to control body temperature supports the use of fezolinetant to directly and safely address the basis for hot flashes in menopausal women. In addition, fezolinetant addresses the cause of PCOS by selectively lowering luteinizing hormone (LH) without affecting follicle-stimulating hormone (FSH) in order to restore the correct LH-to-FSH ratio and permit the restoration of menstrual cycle regularity and fertility. Fezolinetant is also superior to the existing, marketed gonadotropin-releasing hormone (GnRH) ligands as it reduces levels of the ovarian hormones estrogen and progesterone in a non-castrating manner as required for the safe, effective treatment of uterine fibroids and endometriosis.

Zuclomiphene citrate: Veru Inc

Zuclomiphene citrate is a novel, proprietary, oral, nonsteroidal, estrogen receptor agonist. Today the Company announced that a Phase 2 clinical trial of Zuclomiphene citrate demonstrated a statistically significant reduction in the frequency of moderate to severe hot flashes in men with advanced prostate cancer on ADT therapy.

Hot Flashes Key Companies

Veru Healthcare

Fervent Pharmaceuticals

Ogeda

Bayer

Lundbeck A/S

TherapeuticsMD

MenoGeniX

Mitsubishi Tanabe Pharma

QUE Oncology

Pherin Pharmaceuticals

For more information, visit Hot Flashes Market Analysis, Patient Pool, and Emerging Therapies

Trending Reports by DelveInsight:

About DelveInsight:

DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance.

Connect with DelveInsight:

LinkedIn | Facebook | Twitter

Kritika RehaniTeam Lead, Marketing

[email protected]

+91-9650213330

www.delveinsight.com

0 notes